Olema Pharmaceuticals annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Olema Pharmaceuticals R&D Spending Growth & History (OLMA)
Olema Pharmaceuticals's r&d spending was $157.7M for fiscal 2025.
View full Olema Pharmaceuticals company overviewOlema Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $157.7M | $33.2M | +26.65% |
| 2024 | 2024-12-31 | $124.5M | $38.4M | +44.55% |
| 2023 | 2023-12-31 | $86.1M | $3.9M | +4.70% |
| 2022 | 2022-12-31 | $82.3M | $31.2M | +61.01% |
| 2021 | 2021-12-31 | $51.1M | $37.4M | +272.88% |
| 2020 | 2020-12-31 | $13.7M | $9.8M | +249.59% |
| 2019 | 2019-12-31 | $3.9M | — | — |
Olema Pharmaceuticals quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $57.8M | $13.9M | +31.62% |
| Q1 2026 | 2026-03-31 | $49.2M | $18.6M | +60.76% |
| Q4 2025 | 2025-12-31 | $43.2M | $10.9M | +33.81% |
| Q3 2025 | 2025-09-30 | $40.0M | $6.7M | +20.24% |
| Q2 2025 | 2025-06-30 | $43.9M | $14.8M | +50.82% |
| Q1 2025 | 2025-03-31 | $30.6M | $741,000 | +2.48% |
| Q4 2024 | 2024-12-31 | $32.3M | $6.4M | +24.84% |
| Q3 2024 | 2024-09-30 | $33.2M | $13.8M | +70.80% |
| Q2 2024 | 2024-06-30 | $29.1M | $11.1M | +61.82% |
| Q1 2024 | 2024-03-31 | $29.9M | $7.1M | +30.92% |
| Q4 2023 | 2023-12-31 | $25.9M | $4.3M | +19.87% |
| Q3 2023 | 2023-09-30 | $19.5M | $1.8M | +10.36% |
| Q2 2023 | 2023-06-30 | $18.0M | −$9.1M | −33.51% |
| Q1 2023 | 2023-03-31 | $22.8M | $6.8M | +42.58% |
| Q4 2022 | 2022-12-31 | $21.6M | $5.6M | +35.11% |
| Q3 2022 | 2022-09-30 | $17.6M | $5.1M | +40.76% |
| Q2 2022 | 2022-06-30 | $27.1M | $15.1M | +127.15% |
| Q1 2022 | 2022-03-31 | $16.0M | $5.3M | +49.73% |
| Q4 2021 | 2021-12-31 | $16.0M | $9.7M | +154.01% |
| Q3 2021 | 2021-09-30 | $12.5M | $7.8M | +167.99% |
| Q2 2021 | 2021-06-30 | $11.9M | $10.0M | +511.71% |
| Q1 2021 | 2021-03-31 | $10.7M | $9.9M | +1244.91% |
| Q4 2020 | 2020-12-31 | $6.3M | — | — |
| Q3 2020 | 2020-09-30 | $4.7M | — | — |
| Q2 2020 | 2020-06-30 | $1.9M | — | — |
| Q1 2020 | 2020-03-31 | $795,000 | — | — |
Olema Pharmaceuticals r&d spending trends
Over the last five fiscal years, Olema Pharmaceuticals's r&d spending increased from $13.7M to $157.7M, a change of $144.0M. The latest reported quarter, Q2 2026, shows $57.8M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Olema Pharmaceuticals source filings ↗